Properdin (P) was originally described by Pillemer and his colleagues in 1954 as an outgrowth of studies relating t o the inactivation of the third component of complement (C') by Zymosan (Z), an insoluble carbohydrate derived from yeast cell walls, or by a variety of polysaccharides or polysaccharide complexes of microbial and mammalian origin. P was defined by its reaction with Z, and sera were assayed for P by their ability to inactivate C'3 after the addition of Z [39, 401. In addition t o C' inactivation, P was believed to be responsible for many of the biological activities of normal mammalian serum requiring C': the killing of certain bacteria belonging mainly to gramnegative genera, the neutralization of several viruses, the killing of protozoa and the lysis of abnormal red blood cells including those of patients with paroxysmal nocturnal hemoglobinuria and of normal cells treated with tannic acid. Regarded as a new serum factor, P became implicated, chie%y by association, with resistance to infections in animals subjected to irreversible hemorrhagic shock [ll], in patients with severe burns [28] and in patients with pneumococcal pneumonia [16]. It was associated also with the inadequacy of immune mechanisms following x-irradiation [42] and in protection against neoplastic growth [SO]. Excellent summaries of the extensive investigations in these areas relating exclusively t o P have been written [15, 19, 20, 46, 60, 611 as well as comprehensive reviews on antimicrobial serum and tissue factors [48], non-specific resistance [47] and C' [37], which include discussions of P. This review will attempt an assessment of the conceptual aspects involved in the introduction of P as a serological entity, a critical evaluation of the postulated part played by P in various activities of serum and its role